Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 12/20 | 0.46 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 3/20 | 0.40 |
| ▸ | LCK | P06239 | 2/20 | 0.40 |
| ▸ | ITK | Q08881 | 1/20 | 0.39 |
| ▸ | STS | P08842 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21903689 | 0.92 | BTK (0.49) | BTKEGFRLCKITK | |
| SCHEMBL21965766 | 0.92 | BTK (0.49) | BTKEGFRLCKITK | |
| SCHEMBL31684271 | 0.92 | BTK (0.49) | BTKEGFRLCKITK | |
| SCHEMBL21903775 | 0.88 | BTK (0.43) | BTKTNK2EPHX2OPRK1MAPT | |
| SCHEMBL21903524 | 0.87 | EPHX2 (0.44) | BTKEPHX2MAPTSTS | |
| SCHEMBL22902475 | 0.85 | CYP1A2 (0.40) | BTKMAPT | |
| SCHEMBL22009418 | 0.85 | BTK (0.46) | BTKOPRK1 | |
| SCHEMBL21903785 | 0.85 | BTK (0.52) | BTKEGFRLCKITK | |
| SCHEMBL21903789 | 0.85 | BTK (0.52) | BTKEGFRLCKITK | |
| SCHEMBL21903812 | 0.85 | BTK (0.41) | BTKMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3653626-B1 | NOVEL 1H-PYRAZOLOPYRIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | DAEWOONG PHARMACEUTICAL CO LTD (KR) | 2025-09-17 | — | — | EP | disclosed |
| US-11180496-B2 | 1H-pyrazolopyridine derivative and pharmaceutical composition comprising the same | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2021-11-23 | — | — | US | disclosed |
| US-11180496-B2 | 1H-pyrazolopyridine derivative and pharmaceutical composition comprising the same | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2021-11-23 | — | — | US | disclosed |
| EP-3653626-A1 | NOVEL 1H-PYRAZOLOPYRIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | Daewoong Pharmaceutical Co., Ltd. (KR) | 2020-05-20 | — | — | EP | disclosed |
| US-20200140432-A1 | NOVEL 1H-PYRAZOLOPYRIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2020-05-07 | — | — | US | disclosed |
| US-20200140432-A1 | NOVEL 1H-PYRAZOLOPYRIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2020-05-07 | — | — | US | disclosed |
| CN-110914266-A | Novel 1H-pyrazolopyridine derivative and pharmaceutical composition comprising the same | 株式会社大熊制药 | 2020-03-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11180496-B2 | 1H-pyrazolopyridine derivative and pharmaceutical composition comprising the same | PDCD11, DPYD, G6PC1 | BTK 1236/4885TNK2 2841/4885EPHX2 2929/4885 |
| US-20200140432-A1 | NOVEL 1H-PYRAZOLOPYRIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | PDCD11, G6PC1, PPM1D | BTK 1744/4885TNK2 2625/4885EPHX2 3278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.